SCHEMBL2889291

SCHEMBL2889291

Cc1c(C2=CCN(C(=O)OC(C)C)CC2)nnn1-c1ccccc1Cl

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 11/20 0.73
GRM5 P41594 9/20 0.73
HRH1 P35367 1/20 0.54
TMEM97 Q5BJF2 1/20 0.54
BRD4 O60885 1/20 0.39
BRD2 P25440 1/20 0.39
BRD3 Q15059 1/20 0.39
CREBBP Q92793 1/20 0.39
TRPV1 Q8NER1 1/20 0.36
KIT P10721 1/20 0.36
PDK4 Q16654 1/20 0.35
SLC6A15 Q9H2J7 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
KCNH2 Q12809 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
P2RX4 Q99571 1/20 0.34
PDE4B Q07343 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2885670 0.88 GRM1 (0.80) GRM1GRM5HRH1TMEM97BRD4
SCHEMBL12975512 0.86 GRM1 (0.65) GRM1GRM5HRH1TMEM97PDK4
SCHEMBL2885002 0.86 GRM1 (0.69) GRM1GRM5HRH1TMEM97BRD4
SCHEMBL2885810 0.86 GRM1 (0.54) GRM1GRM5HRH1TMEM97TRPV1
SCHEMBL2885377 0.84 GRM1 (1.00) GRM1GRM5HRH1TMEM97TRPV1
SCHEMBL12975607 0.80 GRM1 (0.69) GRM1GRM5HRH1TMEM97
SCHEMBL2887688 0.77 GRM1 (0.68) GRM1GRM5HRH1TMEM97BRD4
SCHEMBL14582020 0.77 GRM1 (0.62) GRM1GRM5HRH1TMEM97TRPV1
SCHEMBL2888899 0.77 GRM1 (0.65) GRM1GRM5HRH1TMEM97TRPV1
SCHEMBL5482882 0.77 LIPE (0.44) GRM1GRM5TRPV1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191389-A1 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US claimed
EP-1764362-A1 BIARYL DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-03-21 EP claimed
US-7858800-B2 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-28 US disclosed
US-7858800-B2 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-28 US disclosed
US-7858800-B2 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-28 US disclosed
US-20070191389-A1 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US disclosed
US-20070191389-A1 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US disclosed
US-20070191389-A1 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 US disclosed
EP-1764362-A1 BIARYL DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-03-21 EP disclosed
EP-1764362-A1 BIARYL DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191389-A1 Biaryl derivatives GRM1, GRIN1, GRIN2B GRM1 1/4885GRM5 26/4885HRH1 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.